Brunat-Mentigny M, Demaille M C, Quitana E, Olive D, Bachelot C, Boitetot A, Gentet J C, Noir P, Roche H, Thyss J P
Centre Léon-Bérard, Lyon, France.
Bull Cancer. 1988;75(2):201-6.
The authors treated 188 patients with osteosarcoma by chemotherapy followed by surgery and additional chemotherapy (Rosen's T regimen). In 14% of cases, infectious, neurologic or cardiac complications were observed, which resulted in death in 2% of the patients. Forty-six per cent responded well to the primary chemotherapy, 76% of which are alive and disease-free, as opposed to merely 42% of the bad responders.
作者采用化疗后手术及额外化疗(罗森T方案)治疗了188例骨肉瘤患者。在14%的病例中观察到感染、神经或心脏并发症,其中2%的患者死亡。46%的患者对初始化疗反应良好,其中76%存活且无疾病,而反应不佳的患者中这一比例仅为42%。